Delivery Order SPE2DB24D9223-SPE2DB25FKEDC

Award Date 3/14/25
Potential Completion Date 4/4/25
Potential Value $15K
Ultimate Awardee
Not listed
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed
Pricing Type
Firm Fixed Price
Place of Performance
Park Ridge, IL 60068, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
Not listed
Legislative Mandate
Not listed
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
This is a firm fixed-price delivery order awarded by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler. The $14,786.04 contract is for the supply of Entyvio 300 mg vials, a biologic medication used to treat certain gastrointestinal conditions. The award is part of DMS Pharmaceutical Group's $499,999,999 indefinite delivery contract (IDC) with the DLA under the SPE2DB program, which allows the agency to issue delivery...
This is a firm fixed-price delivery order awarded by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler. The $94,738.20 award is for the provision of 300 mg vials of the biologic drug Entyvio to support the medical supply needs of military healthcare facilities. DMS Pharmaceutical Group holds a $499,999,999 Indefinite Delivery Contract (IDC) with the DLA under the SPE2DB program, which allows the agency to issue delivery...
This is a firm fixed-price delivery order contract awarded by the Defense Logistics Agency (DLA) under the Medical Supply Chain division to DMS Pharmaceutical Group Inc., a woman-owned small business. The contract, valued at $59,144.16, is for the delivery of 300 mg vials of Entyvio, a prescription biologic medication. This delivery order is part of a larger indefinite delivery contract (IDC) with DMS Pharmaceutical Group, valued at up to $499,999,999, which allows the DLA to issue firm...
This is a firm fixed-price delivery order awarded by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois. The contract, valued at $98,898.60, is for the provision of 300 mg vials of the pharmaceutical drug Entyvio to support the medical supply needs of military healthcare facilities. The contract is not associated with any set-aside designation, allowing DMS Pharmaceutical Group to leverage...
This is a firm fixed-price delivery order awarded by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler. The $98,898.60 contract is for the supply of Entyvio 300 mg vials, a specialized pharmaceutical product, to support the medical needs of military healthcare facilities. DMS Pharmaceutical Group holds a $499,999,999 single-award Indefinite Delivery Contract (IDC) with the DLA under the SPE2DB program, which enables the...
This is a firm fixed-price delivery order contract awarded by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler. The contract is valued at $73,930.20 and has an ultimate completion date of July 1, 2024. The contract is for the delivery of the pharmaceutical product Entyvio 300 mg vials to support the recurring medical supply needs of military health facilities. This delivery order is issued under DMS Pharmaceutical Group's...
This is a firm fixed-price delivery order contract awarded by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois. The contract, valued at $56,842.80, is for the delivery of Entyvio 300 mg vials, a specialty pharmaceutical product. The contract is part of a larger indefinite delivery contract (IDC) vehicle held by DMS Pharmaceutical Group with the DLA, valued at up to $499,999,999, which...
This is a firm fixed-price delivery order awarded by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois. The $89,008.74 contract is for the delivery of 300 mg vials of the prescription drug Entyvio to support the recurring medical supply needs of military healthcare facilities. DMS Pharmaceutical Group holds a $499,999,999 Indefinite Delivery Contract (IDC) with the DLA under the SPE2DB...
This is a firm fixed-price delivery order awarded to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler, by the Defense Logistics Agency (DLA). The $236,576.64 contract is for the supply of Entyvio 300 mg vials, a specialty medication used in the treatment of certain autoimmune conditions. The award is part of a larger $499,999,999 indefinite delivery contract (IDC) held by DMS Pharmaceutical Group with the DLA under the SPE2DB program. This single-award IDC...
This is a firm fixed-price delivery order contract awarded by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois. The contract, valued at $29,572.08, is for the delivery of 300 mg vials of the biologic drug Entyvio. It has an ultimate completion date of January 24, 2024. DMS Pharmaceutical Group Inc. holds a larger $499,999,999 Indefinite Delivery Contract (IDC) with the DLA under the SPE2DB...
  • SPE2DB24D9223
    Indefinite Delivery Contract
  • SPE2DB24D9223-SPE2DB25FKEDC
    Delivery Order

This is a firm fixed-price delivery order awarded by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler. The contract, valued at $14,834.79, is for the provision of 300 mg vials of the biologic drug Entyvio to support the medical supply needs of military healthcare facilities.

The award is part of a larger Indefinite Delivery Contract (IDC) held by DMS Pharmaceutical Group with the DLA under the SPE2DB program, valued at $499,999,999 and valid through November 2026. This IDC enables the DLA to issue firm fixed-price delivery orders for a comprehensive range of pharmaceutical products, including branded and generic prescription drugs, over-the-counter medications, biologics, and medical consumables, to support the medical supply needs of Department of Defense healthcare sites nationwide. The contract does not have a set-aside designation, allowing DMS Pharmaceutical Group to leverage its status as a woman-owned small business to secure direct federal awards across multiple product categories and medical domains.

Generated 6/13/25, 10:04 AM